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Abstract
Purpose: Germline polymorphisms may affect chemothera-
py efﬁcacy and toxicity. We examined the effect of polymorph-
isms in drug metabolism and DNA repair genes on pathologic
response rates, survival, and toxicity for patients randomized to
surgery alone or perioperative ECF chemotherapy in the MRC
MAGIC trial.
Experimental Design: DNA was extracted from nontumor
resection formalin-ﬁxed parafﬁn-embedded (FFPE) blocks.
ERCC1, ERCC2, XRCC1, DYPD, and OPRT SNPs were evaluated
using Sequenom, GSTP1, GSTT1 deletion, and TYMS (TS) 50
2R/3R using multiplex PCR. Post PCR ampliﬁcation, TS 2R/3R
and GSTT1 samples underwent gel electrophoresis.
Results: Polymorphism data were available for 289 of 456
(63.4%) operated patients. No polymorphism was statistically
signiﬁcantly associated with pathologic response to chemother-
apy. Median overall survival (OS) for patients treated with
surgery alone with any TS genotype was not different (1.76
years 2R/2R, 1.68 years 2R/3R, 2.09 years 3R/3R). Median OS
for patients with a TS 2R/2R genotype treated with chemother-
apy was not reached, whereas median OS for 2R/3R and 3R/3R
patients were 1.44 and 1.60 years, respectively (log rank P value
¼ 0.0053). The P value for the interaction between treatment
arm and genotype (3R/3R and 3R/2R vs. 2R/2R) was 0.029. No
polymorphism was statistically signiﬁcantly associated with
chemotherapy toxicity.
Conclusions: In MAGIC, patients with a TS 2R/2R genotype
appeared to derive a larger beneﬁt from perioperative ECF che-
motherapy than patients with 3R containing genotypes. Further
exploration of this potential predictive biomarker in this patient
population is warranted. Clin Cancer Res; 23(24); 7543–9.2017 AACR.
Introduction
Gastric and esophageal cancers are the third and sixth most
common causes of cancer death annually worldwide (1). Neoad-
juvant or perioperative chemotherapy is one standard treatment
for patients with operable gastric or gastroesophageal adenocar-
cinoma prior to surgical resection (2–5). This approach is asso-
ciated with a modest (6–13%) absolute overall survival (OS)
advantage in terms ofOS compared to surgery alone but alsowith
chemotherapy-related toxicities such as nausea and vomiting, and
neutropenia. Furthermore, following multimodality therapy half
of resected patients develop incurable, metastatic cancer, and
therefore do not beneﬁt from neoadjuvant chemotherapy
(2, 4). Better selection of patients for preoperative chemotherapy
might avoid needless toxicity; however, currently, gastroesopha-
geal cancer patients who are treated with neoadjuvant chemo-
therapy are selected for treatment based on radiologic staging
alone as there are no currently validated predictive biomarkers for
chemotherapy.
Germline polymorphisms in genes associated with chemother-
apy and drug metabolism have been validated as predictors of
survival and toxicity outcomes across several tumor types
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including colorectal and breast cancer (6–8). Although similar
studies have examined the effects of polymorphisms in germline
genes relating to chemotherapy metabolism in gastroesophageal
cancer, most of these have been retrospective, and all lack an
untreated control group (9–11). TheUKMRCMAGIC trial was an
open label, multicentre, phase III randomized trial comparing six
cycles of perioperative ECF (epirubicin, cisplatin, and infused 5-
ﬂuorouracil) chemotherapy (three cycles pre- and three cycles
postresection) plus surgery to surgery alone in patients with
resectable gastroesophageal cancer (2). Patients treated with
perioperative chemotherapy had improved OS compared to
patients treated with surgery alone [5-year OS 36% vs. 23%; HR
0.75; 95% conﬁdence interval (CI), 0.60–0.93; P ¼ 0.009]. As a
result, perioperative ECF chemotherapy became one standard
treatment regimen for patients with resectable gastroesophageal
adenocarcinoma. We hypothesized that selected germline poly-
morphisms would be associated with pathologic response to
chemotherapy, OS, or chemotherapy-related toxicity in theMAG-
IC trial, and herein present the results of this analysis.
Methods
Hematoxylin and eosin (H&E)-stained tissue sections from
resection specimens were reviewed by a histopathologist (AW).
DNA was extracted from nonmalignant tissue. Five sections
(10 mm thick) were cut and deparafﬁnized using a standard
protocol, and the area of interest was dissected using a sterile
scalpel blade.GenomicDNAwas extracted using theQIAmpDNA
Micro Kit and QIAamp DNA FFPE Tissue Kit (Qiagen), following
the manufacturer's instructions. After dewaxing and rehydrating
the slides, tissue was microdissected and placed into a 1.5-mL
Eppendorf tube with buffer ATL and proteinase K for digestion
(Qiagen). DNAwas eluted in buffer ATE (Qiagen) with an elution
volume of 60 mL. Quality control of the DNA was performed on
the basis of 260:230 and 260:280 ratio values and visual inspec-
tionof thewavelength spectral patternprovided by theNanoDrop
spectrophotometer (Thermo Scientiﬁc). A 260:230 ratio of
approximately 2.0, together with a 260:280 ratio of approximate-
ly 1.8 and the presence of a peak at 260 nm with a steep decrease
toward 280 nm in the wavelength spectrum was considered
sufﬁciently good quality DNA.
Slides from all cases were reviewed and pathologic response in
tumor graded using theMandard tumor regression grading (TRG)
system (12).
Genotype analysis
Ten polymorphisms were selected based on a review of the
literature and expected interaction with epirubicin, cisplatin, and
5-ﬂuorouracil (5-FU) chemotherapy. These are listed in Table 1.
For detailed description of genotype analysis methodology,
please see Supplementary Methods.
Statistical analysis
OS was calculated from surgery to death from any cause or last
date of follow up. Date of surgery was selected as the baseline for
biomarker analysis to reduce potential bias as only patients with a
surgical specimen were available for inclusion. Analyses were
performed within treatment arms due to the differences in timing
of surgery, to further reduce potential bias in the estimates of
effects. Date of surgery could not be conﬁrmed for nine patients in
the chemotherapy plus surgery arm and these patients were
excluded from the survival analyses. Differences in OS by poly-
morphism status were assessed using the Kaplan–Meier method
and compared using Cox regression. To mitigate multiplicity a
P value of <0.01 was considered signiﬁcant when testing for
associations of genotypes with survival and toxicity, and <0.05
when testing interactions. Multiple imputation was performed to
account formissing polymorphism data. OS results were adjusted
for possible confounders of age, subtype, gender, site of primary,
WHO, nodal status).
Proportions of patients with good pathologic response (TRG
1-2) compared with poor pathologic response (TRG 3-5) were
compared for each genotype using the Fisher exact test. Propor-
tions of patients with toxicities according to genotype were
compared using Pearson chi-squared test or Fisher exact test
where appropriate.
As TS 2R/2R genotype is the polymorphism of interest and is
present in approximately 30% of patients, with median OS of 18
months in control (2R/3Rþ3R/3R), power of 80%, 5% two-sided
signiﬁcance level, to detect an HR of 0.5 would require 85 events.
Alternatively, as with the same assumptions as above with 70%
power, 67 events would be required. With respect to pathologic
response rate in TS genotyped patients, in order to detect a
doubling in response rates from 15% to 30%, 206 patients would
be required to achieve 70% power. This is based on a pathologic
response rate of 15% in the 3R group, which accounts for 70% of
patients, and 30% in the 2R/2R group (which contains 30% of
patients). Because of the trial design and retrospective nature of
these analyses, all results can only be seem as hypothesis
Table 1. Germline polymorphisms analyzed
Gene Polymorphism rsID
OPRT G638C (Gly213Ala) 1801019
DPYD IVS14þ1G>A DPYD2A
DPYD A1627G 1801159
ERCC1 C118T 11615
ERCC1 C8092A 3212986
ERCC2 Lys751Gln 13181
XRCC1 A399G 25487
GSTP1 I105V 1695
TS 2R/3R 50UTR 2R/3R repeat
GSTT1 deletion
Translational Relevance
Neoadjuvant or perioperative cisplatin and 5-ﬂuorouracil–
based chemotherapy plus surgery is one standard of care for
patients with resectable gastroesophageal cancer. However,
chemotherapy beneﬁts only a small proportion of patients,
and validated biomarkers predictive of response or toxicity
have been elusive. We analyzed the effect of multiple germline
polymorphisms putatively associatedwith response or toxicity
to chemotherapy in patients treated with chemotherapy plus
surgery or surgery alone in the UK Medical Research Council
MAGIC Trial. One polymorphism in thymidylate synthase
(TS), a 2R/2R tandem repeat, was signiﬁcantly associated with
overall survival in patients treated with chemotherapy, but not
in patients treated with surgery alone. These ﬁndings suggest
that neoadjuvant chemotherapy for patients with operable
gastroesophageal cancer couldbepersonalized basedongerm-
line polymorphism status.
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generating and suggestive of future work, with signiﬁcance levels
set to limit the possibility of a type II error.
All analyses were conducted using Stata version 14. TheMAGIC
protocol was approved by the relevant ethics committees, and
patients gave written informed consent for participation in the
trial. The translational MAGIC protocol (TransMAGIC) received
separate national ethics approval (11/LO/0566).
Results
Polymorphism data were available for 289/456 (63.4%)
patients who underwent surgery in the MAGIC trial. There was
no difference in distribution of sex, performance status, site of
tumor, age, or treatment arm between patients with and without
polymorphism data; however, patients without polymorphism
data weremore likely to undergo a palliative resection in the view
of the operating surgeon (Supplementary Table S1). This resulted
in a borderline difference in survival between patients who had
polymorphism data available and those who did not, which
was more pronounced in the surgery only arm (Supplementary
Fig. S1).
Discordance in size-based polymorphism assessment
We found that onduplicate runs that size-based polymorphism
assessment that discordance occurred at a rate of 32.7% and 4.2%
for GSTT1 and TYMS (TS), respectively (13). Because of the high
rate of discordance in GSTT1 results for this polymorphism was
not analyzed further.
Genotype frequency
The frequency of each polymorphism genotype is described
in Table 2. Genotype frequency was consistent with previously
published data and all were inHardy–Weinberg equilibriumwith
the exception of DPYD rs1801159.
Genotype and pathologic response to chemotherapy
The association between each polymorphism and pathologic
response to chemotherapy in chemotherapy-treated patients is
described in Table 3. No polymorphism was statistically signif-
icantly associated with pathologic response to chemotherapy.
Genotype and OS
Median OS for patients treated with surgery alone who had TS
2R/2R genotype was 1.76 years, compared to 1.68 years for 2R/3R
and 2.09 years for 3R/3R (Table 4 and Fig. 1). These differences
were not statistically signiﬁcant. In contrast, median OS for
patients with a TS 2R/2R genotype treated with chemotherapy
was not reached, whereas survival for 2R/3R and 3R/3R were 1.44
and1.60 years, respectively (log rankP value 0.0053).When all 3R
genotypes were combined, median OS was 1.44 years for che-
motherapy-treated patients versus not reached for 2R/2R geno-
type (HR ¼ 2.4; P ¼ 0.003). The effect of TS genotype on OS in
chemotherapy-treated patients remained statistically signiﬁcant
when adjusted for the potential confounders of age, subtype,
gender, site of primary, WHO, nodal status (Table 4). The P value
for the interaction between treatment arm and TS genotype
(3R/3R and 3R/2R vs. 2R/2R) was 0.029 (with an HR ¼ 0.46).
To assess the effect of a 4.2% discrepancy in TS genotype status
assessment, we performed 10,000 simulations, randomly chang-
ing 4.2%of results. From these 10,000 simulations, the 2.5 to 97.5
percentiles of the HR for the interaction between treatment arm
and TS genotype (3R/3R and 3R/2R vs. 2R/2R) was 0.37–0.60,
compared to the estimate from the original data of 0.46.
Patients with the (AG) genotype ofDPYD rs1801159 Ile543Val
had numerically shorter survival compared to the AA genotype in
the surgery alone arm of the trial, this difference was statistically
signiﬁcant (HR ¼ 1.75; P ¼ 0.008). There was no evidence of
an interaction between treatment arm and DPYD status. Results
were similar when multiple imputation was performed for miss-
ing data.
Noother genotypewas statistically signiﬁcantly associatedwith
OS (see Supplementary Tables S2A–S2F).
Genotype and chemotherapy-related toxicity
The presence of grade 3 or greater toxicity and association
with polymorphism status are detailed in Supplementary Table
S1. DPYD2A IVS14þ1G>A GA variant was associated with a
nonstatistically signiﬁcant trend towards increased rates of
grade 3 diarrhea (P ¼ 0.039); however, only one patient was
detected with this variant. No other polymorphism demon-
strated a statistically signiﬁcant relationship with chemother-
apy related toxicity.
The mean number of cycles of chemotherapy received for most
polymorphisms was ﬁve (Supplementary Table S3), with the
exception of ERCC1 rs3212986 (GTþTT) variant who had amean
of four cycles (Kruskal–Wallis equality-of-populations rank test,
P ¼ 0.0425).
Table 2. Frequency of each polymorphism
ChemoþSurgery
Surgery
alone Total
TS 2R/3R 50UTR 2R/2R 38 (31%) 53 (36%) 91 (34%)
2R/3R 51 (41%) 61 (42%) 112 (41%)
3R/3R 35 (28%) 32 (22%) 67 (25%)
Total 124 146 270
GSTP1 rs1695 A 74 (56%) 73 (47%) 147 (51%)
AG 53 (40%) 67 (43%) 120 (41%)
G 6 (4%) 16 (10%) 22 (8%)
Total 133 156 289
OPRT rs1801019 C 5 (4%) 3 (2%) 8 (3%)
G 92 (69%) 92 (59%) 184 (64%)
CG 36 (27%) 60 (39%) 96 (33%)
Total 133 155 288
DPYD2A IVS14þ1G>A G 131 (99%) 152 (100%) 283 (>99%)
GA 1 (1%) 0 (0%) 1 (<1%)
Total 132 152 284
DPYD rs1801159 A 96 (73%) 100 (65%) 196 (68%)
AG 27 (20%) 48 (31%) 75 (26%)
G 9 (7%) 7 (4%) 16 (6%)
Total 132 155 287
ERCC1 rs11615 C 19 (14%) 29 (19%) 48 (17%)
CT 70 (53%) 68 (44%) 138 (48%)
T 44 (33%) 57 (37%) 101 (35%)
Total 133 154 287
ERCC1 rs3212986 G 61 (46%) 84 (55%) 145 (51%)
GT 64 (49%) 60 (39%) 124 (43%)
T 7 (5%) 10 (6%) 17 (6%)
Total 132 154 286
ERCC2 rs13181 G 23 (17%) 20 (13%) 43 (15%)
GT 62 (47%) 63 (41%) 125 (44%)
T 48 (36%) 71 (46%) 119 (41%)
Total 133 154 287
XRCC1 rs25487 A 19 (15%) 18 (12%) 37 (13%)
AG 56 (42%) 67 (43%) 123 (43%)
G 57 (43%) 69 (45%) 126 (44%)
Total 132 154 286
Germline Polymorphisms, Toxicity, and Survival in MAGIC
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Discussion
Our study is the ﬁrst to evaluate the association between
germline polymorphisms and pathologic response, OS, and
chemotherapy-related toxicity for patients with operable gas-
troesophageal cancer in a randomized trial with a control
group. We found that patients who have a 2R/2R thymidylate
synthase (TS) genotype who were treated with perioperative
ECF chemotherapy had statistically superior OS compared to
those who had a 2R/3R or 3R/3R genotype. This difference was
not apparent in patients who were treated with surgery alone,
and a signiﬁcant interaction between TS genotype status and
treatment arm was noted. In addition, in our study, patients
with a TS 2R2R genotype had a nonstatistically signiﬁcant
higher rate of good pathologic response (TRG 1–2) at 24%
compared to 3R allele containing patients. These ﬁndings are
important as if validated pharmacogenomic genotyping could
be used in future to select patients who are more likely to
beneﬁt from perioperative chemotherapy.
TS acts to produce thymidylate which is an essential precur-
sor for DNA synthesis. The activity of TS is blocked by 5-
ﬂuorodeoxyuridylate (5FdUMP), the active metabolite of 5-FU
and it is via this mechanism that 5-FU exerts cytotoxicity. The
human thymidylate synthase gene is polymorphic through the
presence of either double (2R) or triplet (3R) 28 base tandem
repeats which are sited upstream of the TS translational start
site (14). These repeats control the transcription and translation
of the TS gene; individuals with 3R tandem repeats have higher
levels of TS expression in tissue and consequently lower rates of
response to ﬂuoropyrimidine chemotherapy (15). Our ﬁndings
are in keeping with this biology. Several other series have
reported comparable improvements in response rates OS sim-
ilar results in gastric cancer patients with the favorable 2R
genotype treated with ﬂuoropyrimidine 5-FU-based chemo-
therapy, however none of these were a randomized trial with
an untreated control group (14–16). However, opposing results
have also been demonstrated (17, 18). Potential reasons for
this include small, heterogeneous, ethnically diverse popula-
tions treated with variable chemotherapy regimens in both
advanced and resectable disease settings, and the addition of
other related polymorphisms such as the TS 30UTR 6 base pair
polymorphism to analyses (19). We caveat our discussion with
an awareness that length based polymorphism assessment
resulted in a discordance rate of 4.2% for TS polymorphism
status. However, as our ﬁndings for the 2R/2R genotype
are quite striking, even when a stringent P value is applied to
Table 3. Genotype and pathologic response to chemotherapy
Genotype TRG 1-2 TRG 3-5 P
OR for
TRG 3-5 95% CI
TS
2R/2R 9 (24.3) 28 (75.7) (0.536) 1.0
2R/3R 8 (16.7) 40 (83.3) 0.384 1.61 0.55–4.68
3R/3R 5 (14.7) 29 (85.3) 0.313 1.86 0.56–6.25
2R/2R 9 (24.3) 28 (75.7) 1.0
2R/3R þ 3R/3R 13 (15.9) 69 (84.2) 0.274 1.71 0.66–4.44
GSTP1 rs1695
A 11 (15.5) 60 (84.5) (0.812) 1.0
AG 10 (20.0) 40 (80.0) 0.520 0.73 0.29–1.89
G 1 (16.7) 5 (83.3) 0.939 0.92 0.10–8.62
OPRT
C 2 (40.0) 3 (60.0) (0.308) 1.0
GC 4 (11.8) 30 (88.2) 0.128 5.0 0.63–39.7
G 16 (18.2) 72 (81.8) 0.249 3.0 0.46–19.5
DPYD rs1801159
A 14 (15.4) 77 (84.6) (0.413) 1.0
AG 5 (18.5) 22 (81.5) 0.698 0.80 0.26–2.46
G 3 (33.3) 6 (66.7) 0.186 0.36 0.08–1.62
ERCC1 rs11615
C 3 (16.7) 15 (83.3) (0.211) 1.0
CT 15 (22.7) 51 (77.3) 0.580 0.68 0.17–2.67
T 4 (9.3) 39 (90.7) 0.417 1.95 0.39–9.77
ERCC1 rs3212986
G 8 (13.6) 51 (86.4) (0.496) 1.0
GT 12 (19.7) 49 (80.3) 0.371 0.64 0.24–1.70
T 2 (28.6) 5 (71.4) 0.308 0.39 0.06–2.38
ERCC2 rs13181
G 3 (14.3) 18 (85.7) (0.879) 1.0
GT 11 (19.0) 47 (81.0) 0.631 0.71 0.18–2.85
T 8 (16.7) 40 (83.3) 0.804 0.83 0.20–3.51
XRCC1 rs25487
A 2 (11.1) 16 (88.9) (0.752) 1.0
AG 10 (18.9) 43 (81.1) 0.453 0.54 0.11–2.72
G 10 (17.9) 46 (82.1) 0.503 0.58 0.11–2.91
Abbreviation: CI, conﬁdence interval.
Table 4. Association between TS genotype and OS (second HR and P value are adjusted for age, subtype, gender, site of primary, WHO, nodal status)
Chemotherapy Surgery alone Overall
2R/2R 2R/3R 3R/3R 2R/2R 2R/3R 3R/3R 2R/2R 2R/3R 3R/3R
Patients 38 (31%) 51 (41%) 35 (28%) 51 (36%) 59 (41%) 32 (23%) 89 (34%) 110 (41%) 67 (25%)
Events 15 36 20 31 38 25 46 74 45
Median survival Not reached 1.44 1.60 1.76 1.68 2.09 3.31 1.62 1.84
Log-rank P value 0.0053 0.7212 0.0326
HR 1 (REF) 2.66 2.10 1 (REF) 1.03 1.23 1 (REF) 1.59 1.53
3.06 2.64 1.07 1.45 1.73 1.79
HR P value 0.002 0.032 0.896 0.448 0.013 0.043
0.001 0.009 0.778 0.190 0.005 0.008
Combined analysis
2R/2R 2R/3R þ 3R/3R 2R/2R 2R/3R þ 3R/3R 2R/2R 2R/3R þ 3R/3R
Patients 38 (31%) 86 51 (36%) 91 89 (34%) 177
Events 15 56 31 63 46 119
Median survival Not reached 1.44 1.76 1.84 3.31 1/71
Log-rank P value 0.002 0.6519 0.009
HR 1 (REF) 2.43 1 (REF) 1.10 1 (REF) 1.57
2.89 1.15 1.75
HR P value 0.003 0.652 0.010
0.001 0.531 0.002
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correct for multiplicity, and were conﬁrmed with repeated
simulation testing to account for any discrepancy in TS geno-
type assessment, we do not think that this is likely to have
unduly affected these results.
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting
enzyme in 5-ﬂuorouracil catabolism and variation in DPD levels
and activity have profound effects of ﬂuoropyrimidine metabo-
lism and toxicity. The most well described of these is a DPYD 2
splice variant polymorphism, which results in a nonfunctional
enzyme and is associated with ﬂuoropyrimidine-related toxicity
in many studies (6, 20–22). Although low patient deleterious
allele frequency and lack of statistical signiﬁcance due to correc-
tion for multiplicity means that we cannot be deﬁnitive in our
conclusions, our results are consistent with these data. However,
we think that these results are of secondary importance to the
survival outcomes presented.
We asked two questions from our dataset: ﬁrst, can geno-
typing be used to differentiate between those who derive a
survival beneﬁt from perioperative chemotherapy and those
who do not; and second, if these genotypes were assessed
preoperatively, would it possible to predict excessive toxicity
prior to commencing chemotherapy? Regarding survival ben-
eﬁt, our ﬁndings relating the favorable effects of the TS 2R/2R
genotype are shared with several other large studies (23).
Therefore, is further validation with a clinical trial required?
One small genotype directed clinical trial clinical trial
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evaluated FOLFOX chemotherapy in 25 patients with TS 2R
containing genotypes (2R/2R and 2R/3R) and found that
radiologic response rates did not differ compared to historical
control (24). However, based on our results only the 2R/2R
genotype would beneﬁt from this approach; this was also
suggested in subgroup analysis of that study. As patients with
3R containing genotypes did not appear to beneﬁt from
ﬂuoropyrimidine-based chemotherapy in MAGIC, we suggest
that alternative treatment options should be evaluated for
these patients. Omitting perioperative chemotherapy
completely is unlikely to be acceptable as many patients
(especially those with proximal tumors) require downstaging
prior to surgical resection. Alternatively, patients with 3R
containing genotypes could be treated with higher doses of
ﬂuoropyrimidines, although this could be result in increased
toxicity. This approach in UGT1A1 genotyped patients has
demonstrated that patients who are wild type or heterozygous
for the deleterious 28 allele can tolerate increased doses of
irinotecan compared to UGT1A1 28 homozygotes (25, 26).
Finally, a non-ﬂuoropyrimidine containing regimen could be
considered; for patients with tumors of the gastroesophageal
junction or esophagus chemoradiotherapy with carboplatin
and paclitaxel would seem a reasonable alternative.
With respect to avoiding toxicity, the relative rarity of alleles
which predict for signiﬁcant toxicity such as DPYD 2A is
associated with signiﬁcant screening costs even when toxicity
is reduced by the use of pre-emptive dose reductions (27). As
such, neither the European Medicines Agency nor the U.S.
Food Drug Administration require testing for DPYD variants
prior to treatment with ﬂuoropyrimidines despite the avail-
ability of advice from expert groups such Clinical Pharmaco-
genetics Implementation Consortium and the Dutch Pharma-
cogenetics Working Group, which provide clinical practice
guidelines on genotype-based drug dosing (28, 29). In the
MAGIC trial, the most common grade 3 or greater chemo-
therapy-associated toxicity was neutropenia, which is likely
to be due to epirubicin and which is not predicted by any of
the polymorphisms which we examined. Therefore, routine
testing for DPYD 2A polymorphisms is unlikely to signiﬁ-
cantly decrease toxicity in patients treated with MAGIC type
chemotherapy.
The interaction between chemotherapy and genotype is
complex, and colored by many other clinical variables such
as age, ethnicity, gender, hepatorenal function, and the inter-
action between individual components of each chemotherapy
regimen. This has profound implications for the accuracy of
toxicity or outcome prediction using genotyping. One poten-
tial ﬂaw relating speciﬁcally to this work is that not all MAGIC
trial participants were included in this study as not all pro-
vided tissue for analysis, therefore we caution that the analysis
could be underpowered to detect small effect sizes. On one
hand, if a patient did not undergo surgery due to failure to
respond to treatment then no tissue was available for analysis.
Alternatively, patients with excessive toxicity due to chemo-
therapy may also have stopped chemotherapy prior to surgery.
These potential biases may be reﬂected in the borderline
improved OS demonstrated for patients with polymorphism
data available. Thus, although germline genotype will not be
altered by treatment, any true assessment of the predictive
power of genotype would preferentially be performed in
pretreatment samples for these reasons. A second issue
relates to the technical challenges associated with length-based
polymorphism assessment; moving forward advances in high
throughput next generation sequencing technologies should
ensure improved accuracy and speed of results with decreased
DNA requirements.
In summary, ours is the ﬁrst study to examine the effect of
germline polymorphisms on pathologic response and survival
outcomes for patients treated with perioperative chemotherapy
for operable esophagogastric cancer, with a randomized control
group. We found that patients with a TS 2R/2R genotype
(representing 34% of the population) had excellent survival
when treated with perioperative ECF chemotherapy. In con-
trast, patients with a 3R containing genotype did not appear to
derive a similar beneﬁt from standard dose ﬂuoropyrimidine-
based chemotherapy when compared to patients treated with
surgery alone. It is salutary to note that despite recent progress
in our understanding of the molecular biology underpinning
gastroesophageal cancer that only one targeted drug, trastuzu-
mab, is licensed in this disease, and that almost all patients will
receive platinum and ﬂuoropyrimidine-based chemotherapy as
a component of their treatment (30, 31). Therefore, use of
available data relating to patient selection for standard of care
chemotherapy to design a prospective would appear to be a
sound choice.
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